Protagonist Therapeutics' EPS has grown by 26% in the past three years, but shareholders suffered a 21% loss. Concerns about the share price not reflecting the positive EPS growth may be raised at the upcoming AGM on June 20.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing